/Nerve Growth Factor And Methods Of Use Thereof For Neurodevelopmental Disabilities Associated With Neonatal Hypoxic-ischemic Encephalopathy
Abstract
The present disclosure relates to nerve growth factor (NGF) for use in the prevention or treatment of neurodevelopmental disabilities associated with neonatal hypoxic-ischemic encephalopathy in a subject, wherein the NGF is administered intranasally to the subject.
Full Text
What is claimed is:
The present disclosure relates to nerve growth factor (NGF) for use in the prevention or treatment of neurodevelopmental disabilities associated with neonatal hypoxic-ischemic encephalopathy in a subject, wherein the NGF is administered intranasally to the subject.
Timeline
Filed
03/10/2026Published
07/02/2026Granted
Not AvailableIPC Codes(4)
C07K 14/48:Nerve growth factor [NGF]
A61K 9/00:Medicinal preparations characterised by special physical form
A61K 38/00:Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K 31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K 31/00; ergoline-based peptides A61K 31/48; containing macromolecular compounds having statistically distributed amino acid units A61K 31/74; medicinal preparations containing antigens or antibodies A61K 39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K 47/00)